^
Association details:
| Biomarker: | TMB-H |
|---|---|
| Cancer: | Biliary Tract Cancer |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) + benmelstobart (APL-502) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis
Published date:
05/01/2022
Excerpt:
Patients with high tumor mutational burden (TMB, ≥5 mutations/Mbp) had a better CBR (70.8% vs. 22.2%), longer OS (14.32 vs. 9.64 months), and a trend towards longer PFS (7.03 vs. 4.06 months)….Anlotinib combined with TQB2450 showed promising efficacy and was well tolerated in advanced BTCs. KRAS mutation and high TMB might serve as predictors of treatment efficacy.
DOI:
10.1002/hep.32548
